Pharmacokinetics and tissue distribution of antimony(V) after multiple intramuscular administrations in the hamster

Saudi Pharmaceutical Journal

Volumn 14, Issue 1, 2006, Pages 52-58

  Al Jaser, May H ^a   Radwan, Mahasen A ^b,c   Zaghloul, Iman Y ^b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antimony; Atomic absorption; Hamsters; Pharmacokinetics; Tissue distribution

Indexed keywords

ANTIMONY; STIBOGLUCONATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HAMSTER; HEART; KIDNEY; KIDNEY PARENCHYMA; LIVER; MALE; NONHUMAN; SKIN; SPLEEN; TISSUE DISTRIBUTION;

EID: 33344474064     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Montalban C, Calleja JL, Erice A, Laguna F, Clotet B, Podzamczer D, Cobo J, Mallolas J, Yebra M, Gallego M. The Co-operative Group for Study of Leishmaniasis in AIDS. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J Infect 1990; 21:261-270.
2. Dedet JP, Lambert M, Pratlong F. Leishmaniose et infection par le virus de 'immunodeficience humaine. Presse Med 1993; 24:1036-1040.
3. Bettini S, Gradoni L. Canine leishmaniasis in the Mediterranean area 359 Allopurinol susceptibility and its implication for human leishmaniasis. Insect Sci Appl 1986; 7:241-245.
4. Baneth G, Dank G, Keren-Komblatt E, Sekeles E, Adini I, Eisenberger CL, Schnur LF, King R, Jaffe CL. Emergence of visceral leishmaniasis in Central Israel. Am J Trop Med Hyg 1998; 59:722-725.
5. Berman JD, Gallalee JF, Gallalee JV. Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. Am J Trop Med Hyg 1988; 39:41-45.
6. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 1988; 10:560-86.
7. Pearson RD, Souza AQ. 1995. Leishmania species: visceral (kala-azar), cutaneous and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. New York, Edinburgh, London: Churchill Livingstone Publ., p.2428-42.
8. Chapman WL, Hanson WL, Alving CR, Hendricks LD. Antileishmanial activity of liposome-encapsulated meglumine antimoniate in the dog. Am. J Vet Res 1984; 45:1028-1030.
9. Valladares JE, Alberola J, Esteban M, Arboix M. Disposition of Antimony after the administration of N-methylglucamine antimoniate to dogs. Vet Rec 1996; 138:181-183. 10.
10. Sampaio RN, de-Paula CD, Sampaio JH, Furtado Rde S, Leal PP, Rosa TT, Rodrigues ME, Veiga JP. The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev Soc Bras Med Trop 1997; 30:457-463.
11. Rees PH, Keating MI, Kager PA, Hockmeyer WT. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 1980; 2:226-229.
12. Pamplin CL, Desjardins R, Chulay J, Tramont E, Hendricks L, Canfield C. Pharmacokinetics of antimony during sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Pharmacol Ther 1981; 29:270-271.
13. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 1988; 82:69-72.
14. World Health Organization. 1997. Control of the leishmaniases. Report of a WHO Expert Committee. WHO Technical Report Series. World Health Organization, Geneva, Switzerland.
15. Al Jaser M, El-Yazigi A, Croft S. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharma Res 1995a; 12:113-116.
16. Al Jaser M, El-Yazigi A, Kojan M, Croft S. Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemother 1995b; 39:516-19.
17. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703.
18. Valladares JE, Riera C, Alberola J, Ga'llego M, Portu's M, Cristo'fol C, Franquelo C, Arboix M. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet Parasitol 1998; 75:33-40.
19. Nieto J, Alvar J, Mullen AB, Carter KC, Rodríguez C, San Andre MI, SanAndre' MD, Baillie, AJ, Gonza'lez F. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob. Agents Chemother 2003; 47:2781-2787.
20. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991; 19:21-50.
21. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd edn, Marcel Dekker, New York, pp. 407-417.
22. Ledoux JM. Features of the comparative Pharmacokinetics of lithium; a potential application of its use in livestock fanning. Medical Hypotheses 2003; 61:278-281.
23. Ehrlich BE, Clausen C, Diamond JM. Lithium Pharmacokinetics: single-dose experiments and analysis using a physiological model. J Pharmacokinet Biopharma 1980; 8: 439-461.
24. Morm_ede P, Ledoux JM. Pharmacokinetics and tissue distribution of lithium in chicken (Gallus domesticus). Comp Biochem Physiol 1981; 69C:353-358.
25. Schou M. Lithium studies. 3. Distribution between serum and tissues. Acta Pharmacol Toxicol 1958; 15:115-124.